Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Quantum BioPharma Strengthens Equity and Liquidity in Q2 2026 as FDA Approves Lucid-MS for Pivotal Phase 2 Clinical Trial

TORONTO, Aug. 14, 2026 (GLOBE NEWSWIRE) — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum” or the “Company”), has reported its financial and operational results for the second quarter of 2026, ended June 30, 2026. As of June 30, 2026, the Company’s combined cash and cash equivalents, and digital assets, totaled approximately US$9.5 […]

We haven't written up this one. Financial Post has the full story — the link below goes straight to it.

Read the original at financialpost.com →

More in Health & Medicine

More from Friday 14 August →